literature

HIV mutation literature information.

Compartmentalization of drug resistance-associated mutations in a treatment-naive HIV-infected female.

PMID: 15242547 2004 AIDS research and human retroviruses

Abstract: On the other hand vaginal virus contained L63P and M184V mutations in protease and reverse transcriptase, respectively.

Abstract: Plasma virus had no mutation in reverse transcriptase and one mutation in protease (L63P).

Crystallization of a non-B and a B mutant HIV protease.

PMID: 15333937 2004 Acta crystallographica. Section D, Biological crystallography

Abstract: the subtype B mutant, with mutations Q7K, S37N, R41K, K45R, I54V, L63P, A71V, V82A and L90M, and the subtype F (wild type), naturally carrying mutations Q7K, I15V, E35D, M36I, S37N, R41K, R57K, D60E, Q61N, I62V, L63S, I64L and L89M, with res

Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.

PMID: 15379553 2004 Biochemistry

Abstract: This variant possessed the ritonavir-resistance-associated mutations in the active-site (V32I and V82A) and nonactive-site mutations (K20R, L33F, M36I, L63P, A71V, and L90M).

Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.

PMID: 15465415 2004 Journal of clinical virology

Abstract: The first virus, which had K20I, M36I and V82I, showed 2.9-fold decreased susceptibility to APV, while the second virus showed 3.9-fold decreased susceptibility to both NFV and RTV, with amino acid substitutions K20I, M36I, L63P and V82I.

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.

PMID: 15479840 2004 Journal of virology

Abstract: To examine the basis for this potency, we solved crystal structures of TMC114 complexed with wt HIV-1 protease and TMC114 and APV complexed with an MDR (L63P, V82T, and I84V) protease variant.

Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil.

PMID: 15761606 2004 Memorias do Instituto Oswaldo Cruz

Abstract: Minor mutations were also found at the protease gene: L10I/V (7%), K20M (2%), M36I (11%), L63P (20%), A71T (2%), and V77I (7%).

A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.

PMID: 12534275 2003 Biochemistry

Abstract: This mutant protease contains 11 mutations, 10 of which are located outside the active site (L10I/M36I/S37D/M46I/R57K/L63P/A71V/G73S/L90M/I93L) and 1 within the active site (I84V).

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

PMID: 12543665 2003 Antimicrobial agents and chemotherapy

Abstract: Baseline PI resistance mutations (L10F/I/V, K20M/R, E35D, R41K, I54V, L63P, V82A/F/T/S, I84V) identified by univariate analysis and included in a genotypic score and APV C(min) at week 8 were predictive of the virological response at week 12.

Rates of transmission of antiretroviral drug resistant strains of HIV-1.

PMID: 12600647 2003 Journal of clinical virology

Abstract: L63P was the most frequently found mutation (46.3%).

Abstract: Secondary mutations/polymorphisms were seen in the PR at position L10I/V, K20R, M36I, L63P, A71T/V, or V77I in 60%.

Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals.

PMID: 12700457 2003 AIDS (London, England)

Abstract: Accessory mutations were found in the PR gene at the following positions: L63P/V/T/A/I [153/345 (44.3%)], M36I/L [149/345 (43.2%)], L10I/F/V [82/345 (23.8%)], V77I [60/345 (17.4%)], A71V/T [11/345 (3.2%)], K20M/R [10/345 (2.9%)], and V82I [4/345 (1.2%)].

Browser Board

Co-occurred Entities

Filtrator